Tumour necrosis factor α gene polymorphisms in rheumatoid arthritis: Association with susceptibility to, or severity of, disease?

British Journal of Rheumatology

Volumn 36, Issue 5, 1997, Pages 516-521

  Brinkman, B M N ^b   Huizinga, T W J ^b   Kurban, S S ^b   Van Der Velde, E A ^b   Schreuder, G M Th ^b   Hazes, J M W ^b   Breedveld, F C ^b   Verweij, C L ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Gene polymorphism; Genetics; Rheumatoid arthritis; Severity; Susceptibility; TNF

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TRANSCRIPTION INITIATION;

ADENINE; ADULT; AGED; ALLELES; ARTHRITIS, RHEUMATOID; BASE SEQUENCE; CASE-CONTROL STUDIES; CYTOSINE; DISEASE PROGRESSION; DISEASE SUSCEPTIBILITY; DNA PRIMERS; FEMALE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENES; GENOTYPE; GUANINE; HLA-DR4 ANTIGEN; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030810790     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Albani S, Carson DA, Roudier J. Genetic and environmental factors in the pathogenesis of rheumatoid arthritis. Rheum Dis Clin North Am 1992;18:729-40.
2. Winchester R. The molecular basis of susceptibility to rheumatoid arthritis. Adv Immunol 1994;56:389-465.
3. Oilier W, Thomson W. Population genetics of rheumatoid arthritis. Rheum Dis Clin North Am 1992;18: 741-59.
4. Saxne T, Palladino MA, Heinegard D, Talal N, Wollheim FA. Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1989;31: 1041-5.
5. Elliot MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Brennan FM. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNFα. Safety, clinical efficacy and regulation of the acute-phase response. Br J Rheumatol 1993;32(suppl.1):107.
6. Elliot MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
7. Keffer J, Probert L, Cazlaris H et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of rheumatoid arthritis. EMBO J 1991;10:4025-31.
8. Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen JA, McDevitt HO. Heritable major histocompatibility complex class H-associated differences in production of tumor necrosis factor α: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA 1990;87:1233-37.
9. Bendtzen K, Morling N, Fromsgaard A et al. Association between HLA-DR2 and production of tumour necrosis factor α and interleukin 1 by mononuclear cells activated by lipopolysaccharide. Scand J Immunol 1988;28:599-606.
10. Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LBA, Duff GW. An allelic polymorphism within the human tumor necrosis factor α promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 1993;177:557-60.
11. D'Alfonso S, Momigliano Richardi P. A polymorphic variation in a putative regulation box of the TNFA promoter region. Immunogenetics 1994;39:150-4.
12. Hamann A, Mantzoros C, Vidal-Puig A, Flier JS. Genetic variability in the TNF-α promoter is not associated with type II diabetes mellitus (NIDDM). Biochem Biophys Res Commun 1995;211:833-9.
13. Brinkman BMN, Kaijzel EL, Huizinga TWJ, Giphart MJ, Breedveld FC, Verweij CL. Detection of a novel C-insertion polymorphism within the human tumor necrosis factor alpha (TNFA) gene. Hum Genet 1995;96:493.
14. Matsuda M, Sakamoto N, Fukamaki Y. δ-Thalassemia caused by disruption of the site for an erythroid-specific transcription factor, GATA-1, in the δ-globin gene promoter. Blood 1992;80:1347-51.
15. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
16. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
17. Maniatis T, Fritsch EF, Sambrook J. Molecular cloning: a laboratory manual. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press, 1982.
18. Verduyn W, Doxiadis IIN, Anholts J et al. Biotinylated DRB sequence-specific oligonucleotides. Comparison to serologic HLA-DR typing of organ donors in Eurotransplant. Hum Immunol 1993;37:59-67.
19. Van der Heijde DMFM, van Riel PLCM, van Leeuwen MA, van 't Hof MA, van Rijswijk MH, van de Putte LBA. Prognostic factors for radiographic joint damage and physical disability in early rheumatoid arthritis: a prospective follow-up study of 147 patients. Br J Rheumatol 1992;31:519-25.
20. Van Zeben D, Hazes JMW, Zwinderman AH et al. Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis. Results of a follow-up study. Arthritis Rheum 1991; 34:822-30.
21. Danis VA, Millington M, Hyland V, Lawford R, Huang Q, Grennan D. Increased frequency of the uncommon allele of a tumour necrosis factor alpha polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Dis Markers 1995;12:127-33.
22. Wilson AG, de Vries N, van de Putte LBA, Duff GW. A tumor necrosis factor α polymorphism is not associated with rheumatoid arthritis. Ann Rheum Dis 1995;54:601-3.